T. Rowe Price Associates’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $133K | Buy |
34,231
+2,753
| +9% | +$10.7K | ﹤0.01% | 2831 |
|
|
2025
Q1 | $158K | Buy |
31,478
+3,332
| +12% | +$16.7K | ﹤0.01% | 2714 |
|
|
2024
Q4 | $203K | Buy |
28,146
+4,158
| +17% | +$30K | ﹤0.01% | 2666 |
|
|
2024
Q3 | $148K | Buy |
23,988
+1,320
| +6% | +$8.14K | ﹤0.01% | 2749 |
|
|
2024
Q2 | $151K | Buy |
22,668
+7,430
| +49% | +$49.5K | ﹤0.01% | 2663 |
|
|
2024
Q1 | $156K | Buy |
15,238
+1,821
| +14% | +$18.6K | ﹤0.01% | 2687 |
|
|
2023
Q4 | $151K | Buy |
13,417
+3,370
| +34% | +$37.9K | ﹤0.01% | 2624 |
|
|
2023
Q3 | $27K | Sell |
10,047
-15,600
| -61% | -$41.9K | ﹤0.01% | 2832 |
|
|
2023
Q2 | $91K | Buy |
25,647
+5,847
| +30% | +$20.7K | ﹤0.01% | 2710 |
|
|
2023
Q1 | $84K | Sell |
19,800
-16,100
| -45% | -$68.3K | ﹤0.01% | 2713 |
|
|
2022
Q4 | $591K | Sell |
35,900
-98,714
| -73% | -$1.63M | ﹤0.01% | 2054 |
|
|
2022
Q3 | $1.72M | Buy |
134,614
+99,014
| +278% | +$1.27M | ﹤0.01% | 1513 |
|
|
2022
Q2 | $417K | Sell |
35,600
-3,453
| -9% | -$40.4K | ﹤0.01% | 2287 |
|
|
2022
Q1 | $238K | Buy |
39,053
+834
| +2% | +$5.08K | ﹤0.01% | 2640 |
|
|
2021
Q4 | $350K | Buy |
38,219
+5,900
| +18% | +$54K | ﹤0.01% | 2536 |
|
|
2021
Q3 | $366K | Buy |
32,319
+334
| +1% | +$3.78K | ﹤0.01% | 2502 |
|
|
2021
Q2 | $315K | Sell |
31,985
-16,115
| -34% | -$159K | ﹤0.01% | 2573 |
|
|
2021
Q1 | $680K | Buy |
48,100
+7,100
| +17% | +$100K | ﹤0.01% | 2218 |
|
|
2020
Q4 | $462K | Buy |
41,000
+24,600
| +150% | +$277K | ﹤0.01% | 2272 |
|
|
2020
Q3 | $216K | Buy |
+16,400
| New | +$216K | ﹤0.01% | 2396 |
|
|
2013
Q3 | – | Sell |
-1,267
| Closed | -$604K | – | 2455 |
|
|
2013
Q2 | $604K | Buy |
+1,267
| New | +$604K | ﹤0.01% | 1798 |
|